Community Health Center Drug Pricing Protection Act
- Sponsor
- Rep. Bergman, Jack [R-MI-1]
- Committees
- Energy and Commerce Committee (primary)
- Last action
- Feb 5, 2026
Bottom line
The bill mandates upfront 340B drug discounts for Federally-qualified health centers, eliminating delayed rebate systems and improving their immediate cash flow.
What it actually does
This bill amends the Public Health Service Act to explicitly require drug manufacturers to provide Federally-qualified health centers (FQHCs) with the 340B discounted price for covered outpatient drugs at the point of purchase. It prohibits any arrangement where FQHCs pay more than the ceiling price upfront and then seek a rebate or reimbursement later, aiming to ensure immediate access to savings.
Proponents argue
Supporters argue that this bill is essential for strengthening the financial stability of FQHCs, which are critical safety-net providers. By ensuring upfront discounts, it improves their cash flow, reduces administrative burdens associated with rebate processing, and allows them to fully realize the intended savings of the 340B program to better serve vulnerable patient populations.
Opponents contend
Opponents, primarily drug manufacturers, may contend that existing rebate systems are sufficient and provide necessary operational flexibility. They might argue that mandating upfront discounts creates undue administrative burdens, disrupts established business practices, or could lead to unintended consequences such as adjustments in list prices or other compensatory measures that could impact the broader drug market.
The bill is very short and its core provisions are easily understood, making it highly accessible for a reader to evaluate quickly.
Section 2(a), amending 42 U.S.C. 256b(a)
Mandating Upfront 340B Discounted Pricing for Federally-Qualified Health Centers
This provision amends the Public Health Service Act to add a new paragraph (11) to Section 340B(a). It explicitly states that the Secretary may not enter into agreements with drug manufacturers that require Federally-qualified health centers (FQHCs) to pay more than the applicable 340B ceiling price for covered outpatient drugs at the exact moment of purchase. This aims to prevent manufacturers from requiring FQHCs to pay the full price initially and then wait for a rebate.
Supporters argue
Proponents argue that this provision ensures FQHCs, which serve millions of low-income and uninsured patients, can immediately access the full benefit of 340B discounts. This direct access to savings is crucial for their financial health and ability to reinvest in patient care, aligning with the original intent of the 340B program to support safety-net providers.
Critics contend
Opponents, particularly drug manufacturers, may argue that mandating upfront discounts removes flexibility in pricing models and could create significant administrative and logistical challenges in ensuring real-time compliance across diverse distribution channels. They might also contend that existing rebate mechanisms, while requiring some administrative effort, are a viable and established method for delivering discounts.
Tradeoffs
The provision balances the desire to enhance the financial stability and operational simplicity for FQHCs against the operational complexities and revenue management practices of drug manufacturers. It seeks to clarify the 'time of purchase' for 340B discounts, which has been a point of contention.